Shots:
- The US FDA has approved Lyrfigtu for the 2L treatment of cholangiocarcinoma (CCA) patients with FGFR2 fusion or rearrangement; US availability is expected by Q4’26
- In the P-I/II (ReFocus) trial, Lyrfigtu showed a cORR of 46%, an mDoR of 11.8mos., & 12mos. PFS rate of 49.2% (mPFS: 11.3mos.), with a predictable and manageable safety profile
- Lyrfigtu is being evaluated in a clinical trial enrolling pts with previously treated, advanced or metastatic non-CCA solid tumors harboring FGFR2 fusions or rearrangements who have not received prior FGFR inhibitors
Ref: Globenewswire | Image: Elevar | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
